EP4114465
And-IFNAR1-lyfjagjafaráætlun til inndælingar í húðbeð
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
21.4.2022EP published:
30.8.2023EP application number:
22724683.2
EP translation filed:
23.10.2023Grant published:
15.11.2023EPO information:
European Patent Register
Max expiry date:
20.4.2042Expiry date:
20.4.2026Next due date:
30.4.2026
Title in English:
ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTIONLanguage of the patent:
English
Timeline
Today
21.4.2022EP application
30.8.2023EP Publication
23.10.2023Translation submitted
15.11.2023Registration published
20.4.2026Expires
Owner
Name:
AstraZeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
LINDHOLM, CatharinaAddress:
SE-151 85 Södertälje, SE
Name:
CHIA, Yen LinAddress:
Wilmington, Delaware 19850-5437, US
Name:
TUMMALA, RajendraAddress:
Wilmington, Delaware 19850-5437, US
Name:
ROSKOS, LorinAddress:
Gaithersburg, Maryland 20878, US
Name:
ALMQUIST, JoachimAddress:
SE-151 85 Södertälje, SE
Name:
ROUSE, TomasAddress:
SE-151 85 Södertälje, SE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
202163178739 PDate:
23.4.2021Country:
US
Number:
202163245285 PDate:
17.9.2021Country:
US
Number:
202163272851 PDate:
28.10.2021Country:
US
Classification
Categories:
A61K 39/395, A61K 31/00, A61K 33/00, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 3
Paid: 22.4.2024
Expires: 20.4.2025
Payer: Árnason Faktor ehf.
Number: 4
Paid: 8.4.2025
Expires: 20.4.2026
Payer: Árnason Faktor ehf.